Please login to the form below

Health Canada

This page shows the latest Health Canada news and features for those working in and with pharma, biotech and healthcare.

The FDA collaborated with the Australian Therapeutic Goods Administration and Health Canada on the review of Calquence.

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Other versions of Zantac have also been recalled in Europe and Canada as well. ... This includes Health Canada, who advised companies to halt manufacturing"until evidence is provided to demonstrate that they do not contain NDMA above acceptable
The Final Frontier

Using Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) database, there are about 350, 000 medical cannabis patients in Canada or 1% of the population (see Figure 1). ... Rohit Khanna is the Managing Director of Catalytic
Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again

Orkambi (ivacaftor/lumacaftor) targets a mutation that around 50% of people with CF in the UK have, and has been shown to improve lung health and reduce hospitalisations. ... NHS England adds that it is not alone in being unable to make the drugs
EMA starts rapid review of Shire’s HAE antibody

Lanadelumab (SHP643) is also being assessed by Health Canada under a priority review application, and was submitted to the FDA last month.
Not in my backyard

And then after two years of doing this from Canada, the Secretary of Health and Human Services would have the authority to permit importation from countries in the Organisation for Economic ... And if 40% of US prescriptions flow through Canada, the

More from news
Approximately 2 fully matching, plus 38 partially matching documents found.

Gathering pace: adaptive pathways

Canada has also been developing the concept under the banner of 'progressive licensing'. ... and Finn Børlum-Kristensen from the European network for health technology assessment and Danish Health and Medicines Authority.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Kite Pharma appoints head of regulatory affairs

international agencies – FDA, EMA/CHMP, Health Canada, and PMDA – at multiple levels will be critical to Kite's further advancement and planning.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...